Riess Jonathan W, Lara Primo N
University of California Davis School of Medicine and UC Davis Comprehensive Cancer Center, Sacramento, CA.
University of California Davis School of Medicine and UC Davis Comprehensive Cancer Center, Sacramento, CA.
Clin Lung Cancer. 2014 Mar;15(2):93-5. doi: 10.1016/j.cllc.2013.12.010. Epub 2014 Jan 3.
Systemic therapy and subsequent survival for patients with extensive-stage small-cell lung cancer (SCLC) are poor and have remained unchanged in the past quarter century. To improve outcomes in these patients, a new drug development paradigm must be adopted that moves away from empiricism and instead focuses on tumor biology and heterogeneity as a means to increase target and drug class diversity. By incorporating tools that have led to new diagnostic and treatment options in non-small-cell lung cancer, there could be hope yet for the future of SCLC therapeutics.
广泛期小细胞肺癌（SCLC）患者的全身治疗及后续生存率较低，且在过去四分之一个世纪里一直没有改善。为了改善这些患者的治疗结果，必须采用一种新的药物开发模式，摒弃经验主义，转而关注肿瘤生物学和异质性，以此增加靶点和药物种类的多样性。通过整合那些在非小细胞肺癌中带来新诊断和治疗选择的工具，SCLC治疗的未来仍有望取得进展。
